212 related articles for article (PubMed ID: 28602170)
1. Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy.
Faugeras L; Dili A; Druez A; Krug B; Decoster C; D'Hondt L
Crit Rev Oncol Hematol; 2017 Jul; 115():59-66. PubMed ID: 28602170
[TBL] [Abstract][Full Text] [Related]
2. Current controversies in the management of metastatic colorectal cancer.
Vera R; Alonso V; Gállego J; González E; Guillén-Ponce C; Pericay C; Rivera F; Safont MJ; Valladares-Ayerbes M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):659-77. PubMed ID: 26113053
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
4. [Systemic therapy for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
[TBL] [Abstract][Full Text] [Related]
5. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.
Moosmann N; Laessig D; Michaely HJ; Schulz C; Heinemann V
Onkologie; 2007 Oct; 30(10):509-12. PubMed ID: 17890890
[TBL] [Abstract][Full Text] [Related]
6. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma.
Tural D; Akar E; Öztürk MA; Yıldız Ö; Turna H; Serdengeçti S
J Cancer Res Ther; 2014; 10(3):745-8. PubMed ID: 25313774
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Nielsen DL; Palshof JA; Larsen FO; Jensen BV; Pfeiffer P
Cancer Treat Rev; 2014 Jul; 40(6):701-15. PubMed ID: 24731471
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
11. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
12. First- and second-line therapy of metastatic colorectal cancer.
Terstriep S; Grothey A
Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
[TBL] [Abstract][Full Text] [Related]
13. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
14. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM; Shastri K; Pilaro AM; Fuchs C; Cordoba-Rodriguez R; Koti K; Rothmann M; Men AY; Zhao H; Hughes M; Keegan P; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Mar; 14(5):1296-302. PubMed ID: 18316547
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
16. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
17. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
Cleary JM; Tanabe KT; Lauwers GY; Zhu AX
Oncologist; 2009 Nov; 14(11):1095-105. PubMed ID: 19880627
[TBL] [Abstract][Full Text] [Related]
18. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
19. [New drugs for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Praxis (Bern 1994); 2004 Sep; 93(36):1455-9. PubMed ID: 15487860
[TBL] [Abstract][Full Text] [Related]
20. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]